A novel near-infrared fluorescence imaging probe that preferentially binds to cannabinoid receptors CB2R over CB1R

被引:23
|
作者
Ling, Xiaoxi [1 ]
Zhang, Shaojuan [1 ]
Shao, Pin [1 ]
Li, Weixia [1 ,2 ]
Yang, Ling [1 ,3 ]
Ding, Ying [4 ]
Xu, Cong [5 ]
Stella, Nephi [5 ]
Bai, Mingfeng [1 ,6 ]
机构
[1] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15219 USA
[2] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Radiol, Shanghai 200025, Peoples R China
[3] Fudan Univ, Basic Med Sch, Cellular & Genet Med Dept, Shanghai 200032, Peoples R China
[4] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA
[5] Univ Washington, Dept Pharmacol Psychiat & Behav Sci, Seattle, WA 98195 USA
[6] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15232 USA
关键词
Cannabinoid; CB2; receptor; Fluorescence imaging; Cancer; Near infrared; ENDOCANNABINOID SYSTEM; LIGAND;
D O I
10.1016/j.biomaterials.2015.04.018
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The type 2 cannabinoid receptors (CB2R) have gained much attention recently due to their important regulatory role in a host of pathophysiological processes. However, the exact biological function of CB2R and how this function might change depending on disease progression remains unclear and could be better studied with highly sensitive and selective imaging tools for identifying the receptors. Here we report the first near infrared fluorescence imaging probe (NIR760-XLP6) that binds preferentially to CB2R over the type 1 cannabinoid receptors (CB1R). The selectivity of the probe was demonstrated by fluorescence microscopy using DBT-CB2 and DBT-CB1 cells. Furthermore, in mouse tumor models, NIR760-XLP6 showed significantly higher uptake in DBT-CB2 than that in DBT-CB1 tumors. These findings indicate that NIR760-XLP6 is a promising imaging tool for the study of CB2R regulation. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:169 / 178
页数:10
相关论文
共 50 条
  • [21] In vivo inflammation imaging using a CB2R-targeted near infrared fluorescent probe
    Zhang, Shaojuan
    Shao, Pin
    Ling, Xiaoxi
    Yang, Ling
    Hou, Weizhou
    Thorne, Steve H.
    Beaino, Wissam
    Anderson, Carolyn J.
    Ding, Ying
    Bai, Mingfeng
    AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 5 (03): : 246 - 258
  • [22] Novel Treatment Strategy For Pulmonary Fibrosis By A Hybrid Inhibitor Of Peripheral Cannabinoid-1-Receptors (cb1r) And Inducible No Synthase (INOS)
    Cinar, R.
    Gochuico, B. R.
    Iyer, M. R.
    Park, J. K.
    Gahi, W. A.
    Kunos, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [23] ACTIVATION OF ADIPOSE TISSUE CANNABINOID RECEPTORS 1 (CB1R) ALTERS ANTILIPOLYTIC ACTION OF INSULIN AND INCREASES LIPOLYSIS IN MICE
    Muller, T.
    Troy-Fioramonti, S.
    Demizieux, L.
    Gresti, J.
    Bouam, M.
    Verges, B.
    Degrace, P.
    ATHEROSCLEROSIS, 2014, 235 (02) : E53 - E53
  • [24] Activation of adipose tissue cannabinoid receptors 1 (CB1R) alters antilipolytic action of insulin and increases lipolysis in mice
    Degrace, P.
    Muller, T.
    Troy-Fioramonti, S.
    Demizieux, L.
    Gresti, J.
    Bouam, M.
    Verges, B.
    DIABETOLOGIA, 2014, 57 : S290 - S290
  • [25] Novel treatment strategy for liver fibrosis by hybrid inhibitors targeting peripheral cannabinoid-1 receptors (CB1R) and inducible NO synthase (iNOS)
    Cinar, Resat
    Iyer, Malliga
    Liu, Ziyi
    Jourdan, Tony
    Cao, Zongxian
    Erdelyi, Katalin
    Godlewski, Grzegorz
    Szanda, Gergo
    Liu, Jie
    Pacher, Pal
    Rice, Kenner
    Kunos, George
    HEPATOLOGY, 2015, 62 : 883A - 884A
  • [26] Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB2R)
    Ferrisi, Rebecca
    Gado, Francesca
    Polini, Beatrice
    Ricardi, Caterina
    Mohamed, Kawthar A. A.
    Stevenson, Lesley A. A.
    Ortore, Gabriella
    Rapposelli, Simona
    Saccomanni, Giuseppe
    Pertwee, Roger G. G.
    Laprairie, Robert B. B.
    Manera, Clementina
    Chiellini, Grazia
    FRONTIERS IN CHEMISTRY, 2022, 10
  • [27] Activation of type 2 cannabinoid receptors (CB2R) promotes fatty acid oxidation through the SIRT1/PGC-1α pathway
    Zheng, Xuqin
    Sun, Tao
    Wang, Xiaodong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 436 (03) : 377 - 381
  • [28] CP-945,598, a novel cannabinoid CB1 receptor (CB1 R) antagonist, reduces markers of diabetes by preferentially reducing fat mass
    Patterson, Terrell A.
    Hadcock, John R.
    Scott, Dennis O.
    Maurer, Tristan
    Griffith, David A.
    Gibbons, Colleen
    Sullivan, Dawn-Kelly
    Tomlinson, Elizabeth
    DIABETES, 2008, 57 : A481 - A481
  • [29] Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist
    Addy, Carol
    Jumes, Patricia
    Rosko, Kimberly
    Li, Susie
    Li, Hankun
    Maes, Andrea
    Johnson-Levonas, Amy O.
    Chodakewitz, Jeffrey
    Stoch, Aubrey
    Wagner, John A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (10): : 1228 - 1238
  • [30] Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes
    Liu, Qing-Rong
    Aseer, Kanikkai Raja
    Yao, Qin
    Zhong, Xiaoming
    Ghosh, Paritosh
    O'Connell, Jennifer F.
    Egan, Josephine M.
    FRONTIERS IN PHARMACOLOGY, 2022, 12